Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pemphigus Treatment

A pemphigus therapy technology, applied in the field of pemphigus treatment, can solve problems such as adverse effects, delayed clinical response to rituximab, and expensive IVIG therapy

Active Publication Date: 2021-01-29
PRINCIPIA BIOPHARMA
View PDF21 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Disadvantages of the above regimens are that IVIG therapy is expensive and has adverse effects such as headache, back pain, flushing, fever, nausea and vomiting, anaphylaxis, aseptic meningitis, kidney failure, and high blood pressure (see product label) , and clinical response to rituximab was significantly delayed (maximum effect achieved at 8-12 weeks, see Lundardon and Payne AS G Ital Dermatol Venereol "2012; 147(3):269-276), thus requiring corticosteroid therapy lasting several months, and moreover, the durability of response as measured by anti-keratinocytes varies from no relapse to multiple relapses

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pemphigus Treatment
  • Pemphigus Treatment
  • Pemphigus Treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0012] Accordingly, in a first aspect there is provided a method of treating an autoimmune blistering disease in a mammal in need thereof, said method comprising administering to said mammal in need of said treatment a therapeutically effective amount of a BTK inhibitor .

[0013] In a second aspect, there is provided a method of treating acute inflammatory and / or autoimmune diseases in a mammal in need thereof, wherein corticosteroid therapy is used as first-line or second-line therapy, said method comprising introducing The treated mammal is administered a therapeutically effective amount of a BTK inhibitor instead of or in combination with the corticosteroid therapy; and

[0014] The BTK inhibitor is optionally administered in combination with a non-corticosteroid immunosuppressant and / or anti-inflammatory agent.

[0015] In a third aspect, there is provided a method of treating an inflammatory and / or autoimmune disease (wherein corticosteroid therapy is used as first-line...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
Login to View More

Abstract

The present invention provides methods of treating blistering diseases, especially pemphigus vulgaris or pemphigus foliaceous, with BTK inhibitors in mammals; BTK inhibitors as use in diseases treatable with corticosteroids Use in alternative therapy of corticosteroid therapy (such as autoimmune or inflammatory diseases and especially diseases in which corticosteroids are used as first-line or second-line therapy); and pharmaceutical formulations comprising the same.

Description

technical field [0001] This application claims priority to US Provisional Patent Application Serial No. 62 / 093,891, filed December 18, 2014; the contents of which are incorporated herein by reference. [0002] The present invention provides methods of treating blistering diseases, especially pemphigus vulgaris or pemphigus foliaceous, with BTK inhibitors in mammals; BTK inhibitors as use in diseases treatable with corticosteroids Use in alternative therapy of corticosteroid therapy (such as autoimmune or inflammatory diseases and especially diseases in which corticosteroids are used as first-line or second-line therapy); and pharmaceutical formulations comprising the same. Background technique [0003] Pemphigus vulgaris (PV) is a tissue-specific autoimmune blistering disease of the skin and mucous membranes in humans (Scully C, Challacombe S.J. Pemphigus vulgaris: Pathogenesis, oral manifestations and control (Pemphigus vulgaris: update on etiopathogenesis, oral manifestat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4985A61K31/505A61K31/4545A61K31/519A61K38/00A61K45/06A61P29/00A61P37/00
CPCA61K31/4545A61K31/4985A61K31/505A61K31/519A61K38/00A61K45/06A61K2300/00A61P29/00A61P37/00A61P37/06
Inventor S·古尔利
Owner PRINCIPIA BIOPHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com